Welcome to our dedicated page for Outset Medical SEC filings (Ticker: OM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to locate how many Tablo consoles Outset Medical shipped last quarter or what the FDA required in its latest warning letter can mean wading through hundreds of pages. Outset Medical SEC filings are especially dense because they blend medical-device regulations, reimbursement economics and consumable margin data. That complexity is the problem we solve. Our AI-powered summaries translate each section of every document into plain English so you can move straight to the numbers that matter.
Whether you need the Outset Medical quarterly earnings report 10-Q filing or want an Outset Medical annual report 10-K simplified, the platform delivers real-time documents from EDGAR and instant, sentence-by-sentence explanations. Form types are tied to practical questions: 8-Ks flag new FDA clearances—see “Outset Medical 8-K material events explained.” Proxy statements break down incentive plans—explore “Outset Medical proxy statement executive compensation.” And if you are tracking leadership conviction, our dashboard highlights “Outset Medical insider trading Form 4 transactions,” including “Outset Medical executive stock transactions Form 4,” with alerts the moment they post.
Advanced tools layer expert context on top of filings. Interactive charts compare segment margins over time, and AI callouts spotlight supply-chain risk buried deep in footnotes—perfect for “understanding Outset Medical SEC documents with AI.” Need a quick share with colleagues? One-click exports package the full “Outset Medical earnings report filing analysis.” Because updates stream continuously, you never miss an “Outset Medical Form 4 insider transactions real-time.” Complex dialysis disclosures, simplified: that’s the Stock Titan advantage.
The Vanguard Group has filed a Schedule 13G declaring a passive 5.06 % beneficial ownership of Penns Woods Bancorp (PWOD) common stock as of 30 June 2025. The position totals 385,829 shares (CUSIP 708430103).
Voting authority is negligible: 0 shares with sole voting power and 3,071 shares with shared voting power. Conversely, Vanguard controls disposal of nearly the entire holding, with 380,420 shares under sole dispositive power and 5,409 shares under shared dispositive power. The firm certifies the stake was acquired in the ordinary course of business and not to influence control of the issuer.
Crossing the 5 % threshold elevates Vanguard to PWOD’s list of significant shareholders, potentially supporting liquidity and signalling institutional confidence, but the passive filing and limited voting rights suggest only modest governance impact.
FAQ
What is the current stock price of Outset Medical (OM)?
What is the market cap of Outset Medical (OM)?
What is the primary focus of Outset Medical, Inc.?
How does the Tablo system differentiate itself from traditional dialysis machines?
Who are the typical users of Outset Medical's technology?
What are the primary revenue streams for Outset Medical?
How does Outset Medical ensure its products are user-friendly?
In what ways does Tablo enhance operational efficiency?
How does the company integrate advanced technology into its solutions?
What competitive advantages does Outset Medical hold in the healthcare market?
